Navigation Links
Cambrex Zenara Supplies Product for Launch of Nicorette® in India
Date:1/6/2011

EAST RUTHERFORD, N.J., LONDON, and HYDERABAD, India, Jan. 6, 2011 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) announced today that Cambrex Zenara is supplying product for Johnson & Johnson Limited's launch of Nicorette®, a leading smoking cessation product, in India.  The Nicorette® product is being manufactured and packaged by Cambrex Zenara in its Hyderabad, India facility.

"Nicotine Replacement Therapeutics represent an important part of our product portfolio," commented Steven M. Klosk, President and CEO of Cambrex. "It is estimated that India has over 270 million tobacco users, second only to China, and we are proud to supply product for Johnson & Johnson's launch of Nicorette® in this market."

Ashok Narasimhan, President of Cambrex Zenara said, "Being selected by Johnson & Johnson as their manufacturing partner is a testament to Cambrex Zenara's ability to supply product for a well-known brand to a very large market. This demonstrates our commitment to provide high quality, affordable solutions for smoking cessation."

About Cambrex Zenara

Cambrex Zenara develops and manufactures NRT products and provides high quality and competitively priced pharmaceutical drug product, formulation, development and manufacturing capabilities designed to accelerate commercialization of finished dosage forms for the pharmaceutical industry.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potenc
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
2. Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009
3. Cambrex Reports Third Quarter 2009 Results
4. Cambrex Acquires IEP GmbH
5. Cambrex to Announce Third Quarter 2010 Financial Results on November 3, 2010
6. Cambrex Acquires Stake in Zenara Pharma
7. Reportlinker Adds US Disposable Medical Supplies Market Report
8. Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits"
9. First Choice ER to Donate Over $15,000 in Medical Supplies to Haitian Earthquake Victims
10. Henry Schein Works With Supplier Partners to Earmark $1 Million in Health Care Supplies for Haiti Earthquake Relief
11. Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... highlighted findings from a pre-clinical study published in ... Sciences ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ... anti-PD-L1 antibody (a checkpoint inhibitor), suppression of tumor ... be achieved when treating certain hematologic cancers and ...
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today ... operating loss (NOL) guidance and its cash guidance ending ... improved financial results were due in large part to ... received from its partners.  Isis, pro forma NOL of ... over its 2013 NOL of $40.2 million. On a ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... 9, 2011 Vyatta , ... and cloud infrastructures, today announced that the Vyatta ... selected to provide HIPAA compliant network security for ... information technology to deploy scalable, collaborative healthcare networks ...
... AMBLER, Pa., Aug. 9, 2011 Allergy Technologies LLC, ... liners, is sponsoring a new bed bug research program at ... by the Company. This new endeavor will ... strategies relating to innovative bed bug treatment applications. The dramatic ...
Cached Medicine Technology:Vyatta Virtual Firewall Addresses HIPAA Compliance for Thrasys 2Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs 2
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The Heart ... now a distributor of the machine. The Heart Fit ... their license, like a franchise model. The goal is ... and reverse heart disease. To buy External Counterpulsation ... Clinic can help individuals through this process and achieve ...
(Date:2/28/2015)... Fredericton, NB (PRWEB) February 28, 2015 ... call center software suite for Asterisk, are pleased to ... the highly successful 5.7 and 5.8 versions of Q-Suite, ... as well as a number of new features to ... be Q2 2015. , Q-Suite 5.9 will add features ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 ... of outsourced sales, marketing and supply chain management ... BIOTA Botanicals, is bringing its award winning solutions ... BIOTA Botanicals’ products are specifically created to combat ... experts, BIOTA is committed to marrying science with ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... Save the Children By Charles ... WESPORT, Conn., Oct. 24 The dramatic images,of wildfires ... on,children not only in the immediate area where the ... country who are watching the,destructive power of the flames ...
... Company Becomes First to Leverage Zagat,s, Expertise to Survey ... Rate Experiences Using ... Oct. 24 WellPoint, Inc., the,nation,s largest health benefits ... of a new online survey tool that will allow,consumers ...
... Pennsylvania has reversed the medical malpractice trend, ... said that Medical Care Availability and Reduction of ... since he took office and, as,a result of ... "Pennsylvania is a success story when it ...
... a novel,medical humidifier, was awarded a prestigious R&D ... PARI Innovative Manufacturers, a leading,manufacturer of nebulizers and ... gases are heated and humidified with the aim ... greater control,of patient comfort. The award, selected ...
... -- Combat physicians in war-torn areas like Iraq and ... require massive blood transfusions (MT), and thereby increase a ... the October issue of The Journal of the American ... of a combination of three variables -- assessed immediately ...
... induced in healthy volunteers, according to a study by ... Center for Medical Cannabis Research (CMCR.) However, the ... the placebo controlled study of 15 subjects, a low ... provided moderate pain relief, and a high dose increased ...
Cached Medicine News:Health News:How to Help Children Cope With the California Wildfires 2Health News:How to Help Children Cope With the California Wildfires 3Health News:How to Help Children Cope With the California Wildfires 4Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 2Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 3Health News:Governor Rendell Says Mcare Claims and Costs Are 50 Percent Lower Than in 2003 2Health News:PARI's Hydrate Wins Prestigious R&D 100 Award 2Health News:Early predictive model may be new 'weapon' against leading cause of death on battlefield 2Health News:Smoked cannabis proven effective in treating neuropathic pain 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: